Surprise victory: FDA panel backs Mannkind's Afrezza; shares soar
This article was originally published in Scrip
Executive Summary
A panel of advisers to the FDA on 1 April surprised almost everyone by backing approval of Mannkind's experimental inhaled insulin Afrezza (insulin human [rDNA origin]) for type 1 and type 2 diabetes – triggering loud gasps and cheers from the audience, which consisted of several patients and advocates.